We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$395M
AUM Growth
-$219M
Cap. Flow
-$156M
Cap. Flow %
-39.58%
Top 10 Hldgs %
44.14%
Holding
133
New
27
Increased
24
Reduced
29
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.2M
2
CELG
Celgene Corp
CELG
+$7.8M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.42M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$5.26M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$16.1M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
BIIB icon
Biogen
BIIB
+$15.7M
4
PFE icon
Pfizer
PFE
+$14.4M
5
AMGN icon
Amgen
AMGN
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 60.69%
2 Technology 5.44%
3 Communication Services 2.79%
4 Industrials 1.83%
5 Consumer Discretionary 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NDRM
26
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.91M 0.99%
175,951
-77,562
-31% -$1.45M
IMMU
27
DELISTED
Immunomedics Inc
IMMU
$3.85M 0.98%
1,050,000
+650,000
+163% +$1.92M
FOMX
28
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.8M 0.96%
342,000
– –
UNP icon
29
Union Pacific
UNP
$174B
$3.74M 0.95%
36,076
-1,199
-3% -$118K
BMRN icon
30
BioMarin Pharmaceuticals
BMRN
$11.6B
$3.73M 0.94%
+45,000
New +$3.87M
ARAV
31
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.73M 0.94%
41,667
+8,334
+25% +$631K
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$3.63M 0.92%
730,000
-175,000
-19% -$1.21M
KYNB
33
Kyntra Bio
KYNB
$27.2M
$3.33M 0.84%
6,228
+400
+7% +$200K
VRTX icon
34
Vertex Pharmaceuticals
VRTX
$121B
$3.31M 0.84%
+45,000
New +$3.66M
FIS icon
35
Fidelity National Information Services
FIS
$23.1B
$3.29M 0.83%
43,503
-4,657
-10% -$355K
APD icon
36
Air Products & Chemicals
APD
$65.7B
$3.04M 0.77%
21,165
-1,585
-7% -$222K
SLB icon
37
SLB Ltd
SLB
$73.6B
$2.88M 0.73%
+34,361
New +$2.82M
GNCA
38
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.87M 0.73%
87,034
+10,875
+14% +$358K
DBVT
39
DBV Technologies
DBVT
$799M
$2.78M 0.7%
7,906
– –
TVTX icon
40
Travere Therapeutics
TVTX
$5.2B
$2.73M 0.69%
143,974
-46,026
-24% -$941K
AAP icon
41
Advance Auto Parts
AAP
$3.35B
$2.72M 0.69%
16,059
+1,490
+10% +$234K
TSRO
42
DELISTED
TESARO, Inc.
TSRO
$2.69M 0.68%
20,000
-30,000
-60% -$3.78M
CLSD
43
DELISTED
Clearside Biomedical
CLSD
$2.68M 0.68%
20,000
+4,927
+33% +$1.24M
NICE icon
44
Nice
NICE
$5.79B
$2.63M 0.67%
38,323
-47,717
-55% -$3.19M
XLRN
45
DELISTED
Acceleron Pharma
XLRN
$2.55M 0.65%
+100,000
New +$3.17M
SBUX icon
46
Starbucks
SBUX
$120B
$2.53M 0.64%
45,631
+4,031
+10% +$223K
XENE icon
47
Xenon Pharmaceuticals
XENE
$6.06B
$2.53M 0.64%
328,029
+100,000
+44% +$803K
RCKT icon
48
Rocket Pharmaceuticals
RCKT
$340M
$2.45M 0.62%
100,441
– –
GNMX
49
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2.33M 0.59%
450,000
– –
PTLA
50
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.24M 0.57%
+100,000
New +$1.95M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sphera Funds Management held 133 positions worth $395M, down 36% from $614M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management withdrew a net $156M in Q4 2016, closing 30 positions and reducing 29 holdings. Its most notable exit was Allergan plc, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in BioMarin Pharmaceuticals worth $3.73M.

  • Sphera Funds Management's largest Q4 2016 buy was BioMarin Pharmaceuticals: 45,000 shares worth $3.73M.
  • Sphera Funds Management added most to Merck in Q4 2016, an estimated $9.2M increase.
  • Sphera Funds Management's biggest Q4 2016 reduction was Achaogen Inc, cutting an estimated $5.39M.
  • Sphera Funds Management fully exited Allergan plc in Q4 2016, selling an estimated $16.1M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $395M portfolio in Q4 2016.
  • Sphera Funds Management opened 27 new positions and closed 30 in Q4 2016.
  • Sphera Funds Management's portfolio value fell 36% quarter-over-quarter to $395M.

Based on Sphera Funds Management's 13F filing for Q4 2016, filed 13 Feb 2017.